Therapeutic Potential and Anti-Amyloidosis Mechanisms of Tert-Butylhydroquinone for Alzheimer’s Disease

od Akhter, Hasina, Katre, Ashwini, Li, Ling, Liu, Xuebo, Liu, Rui-Ming
Izdano 2011

Increased transforming growth factor beta 1 expression mediates ozone-induced airway fibrosis in mice

od Katre, Ashwini, Ballinger, Carol, Akhter, Hasina, Fanucchi, Michelle, Kim, Dae-Kee, Postlethwait, Edward, Liu, Rui-Ming
Izdano 2011

Large, Non-Cavity Distorting Intramural Leiomyomas Decrease Leukemia Inhibitory Factor in the Secretory Phase Endometrium

od Pier, Bruce, Crellin, Christopher, Katre, Ashwini, Conner, Michael G., Novak, Lea, Young, Steven L, Arend, Rebecca
izdano v Reprod Sci (2020)

Stem cell pathways contribute to clinical chemoresistance in ovarian cancer

od Steg, Adam D., Bevis, Kerri S., Katre, Ashwini A., Ziebarth, Angela, Alvarez, Ronald D., Zhang, Kui, Conner, Michael, Landen, Charles N.
Izdano 2011

Proteasome inhibition reverses hedgehog inhibitor and taxane resistance in ovarian cancer

od Steg, Adam D., Burke, Mata R., Amm, Hope M., Katre, Ashwini A., Dobbin, Zachary C., Jeong, Dae Hoon, Landen, Charles N.
Izdano 2014

B7-H3-targeted (212)Pb radioimmunotherapy of ovarian cancer in preclinical models

od Kasten, Benjamin B., Arend, Rebecca C., Katre, Ashwini A., Kim, Harrison, Fan, Jinda, Ferrone, Soldano, Zinn, Kurt R., Buchsbaum, Donald J.
izdano v Nucl Med Biol (2017)

Smoothened Antagonists Reverse Taxane Resistance in Ovarian Cancer

od Steg, Adam D., Katre, Ashwini A., Bevis, Kerri S., Ziebarth, Angela, Dobbin, Zachary C., Shah, Monjri M., Alvarez, Ronald D., Landen, Charles N.
Izdano 2012

An ex vivo assay of XRT-induced Rad51 foci formation predicts response to PARP-inhibition in ovarian cancer

od Shah, Monjri M., Dobbin, Zachary C., Nowsheen, Somaira, Wielgos, Monica, Katre, Ashwini A., Alvarez, Ronald D., Konstantinopoulos, Panagiotis A., Yang, Eddy S., Landen, Charles N.
izdano v Gynecol Oncol (2014)

Class I histone deacetylase inhibition promotes CD8 T cell activation in ovarian cancer

od McCaw, Tyler R., Goel, Nidhi, Brooke, Dewey J., Katre, Ashwini A., Londoño, Angelina I., Smith, Haller J., Randall, Troy D., Arend, Rebecca C.
izdano v Cancer Med (2020)

Neutralization of TGF-β improves tumor immunity and reduces tumor progression in ovarian carcinoma

od Roane, Brandon M., Meza-Perez, Selene, Katre, Ashwini A., Goldsberry, Whitney N., Randall, Troy D., Norian, Lyse A., Birrer, Michael J., Arend, Rebecca C.
izdano v Mol Cancer Ther (2020)

Using heterogeneity of the patient-derived xenograft model to identify the chemoresistant population in ovarian cancer

od Dobbin, Zachary C., Katre, Ashwini A., Steg, Adam D., Erickson, Britt K., Shah, Monjri M., Alvarez, Ronald D., Conner, Michael G., Schneider, David, Chen, Dongquan, Landen, Charles N.
izdano v Oncotarget (2014)

TARGETING RNA-POLYMERASE I IN BOTH CHEMOSENSITIVE AND CHEMORESISTANT POPULATIONS IN EPITHELIAL OVARIAN CANCER

od Cornelison, Robert, Dobbin, Zachary C., Katre, Ashwini A., Jeong, Dae Hoon, Zhang, Yinfeng, Chen, Dongquan, Petrova, Yuliya, Llaneza, Danielle C., Steg, Adam D., Parsons, Laura, Schneider, David A., Landen, Charles N.
izdano v Clin Cancer Res (2017)

Targeting the Notch Ligand Jagged1 in Both Tumor Cells and Stroma in Ovarian Cancer

od Steg, Adam D., Katre, Ashwini A., Goodman, Blake, Han, Hee-Dong, Nick, Alpa M., Stone, Rebecca L., Coleman, Robert L., Alvarez, Ronald D., Lopez-Berestein, Gabriel, Sood, Anil K., Landen, Charles N.
Izdano 2011

Endoglin (CD105) contributes to platinum resistance and is a target for tumor-specific therapy in epithelial ovarian cancer

od Ziebarth, Angela J., Nowsheen, Somaira, Steg, Adam D., Shah, Monjri M., Katre, Ashwini A., Dobbin, Zachary C., Han, Hee-Dong, Lopez-Berestein, Gabriel, Sood, Anil K., Conner, Michael, Yang, Eddy S., Landen, Charles N.
Izdano 2012

Epigenetic modifiers upregulate MHC II and impede ovarian cancer tumor growth

od Turner, Taylor B, Meza-Perez, Selene, Londoño, Angelina, Katre, Ashwini, Peabody, Jacelyn E., Smith, Haller J., Forero, Andres, Norian, Lyse A, Straughn, J. Michael, Buchsbaum, Donald J., Rand all, Troy D., Arend, Rebecca C.
izdano v Oncotarget (2017)

The anti-tumor effects of entinostat in ovarian cancer require adaptive immunity

od Smith, Haller J., McCaw, Tyler R., Londono, Angelina I., Katre, Ashwini A., Meza-Perez, Selene, Yang, Eddy S., Forero, Andres, Buchsbaum, Donald J., Randall, Troy D., Straughn, J. Michael, Norian, Lyse A., Arend, Rebecca C.
izdano v Cancer (2018)

FTY720 enhances the anti-tumor activity of carboplatin and tamoxifen in a patient-derived xenograft model of ovarian cancer

od Kreitzburg, Kelly M., Fehling, Samuel C., Landen, Charles N., Gamblin, Tracy L., Vance, Rebecca B., Arend, Rebecca C., Katre, Ashwini A., Oliver, Patsy G., van Waardenburg, Robert C.A.M, Alvarez, Ronald D., Yoon, Karina J.
izdano v Cancer Lett (2018)

Inhibiting WNT Ligand Production for Improved Immune Recognition in the Ovarian Tumor Microenvironment

od Goldsberry, Whitney N., Meza-Perez, Selene, Londoño, Angelina I., Katre, Ashwini A., Mott, Bryan T., Roane, Brandon M., Goel, Nidhi, Wall, Jaclyn A., Cooper, Sara J., Norian, Lyse A., Randall, Troy D., Birrer, Michael J., Arend, Rebecca C.
izdano v Cancers (Basel) (2020)

Niclosamide and its analogs are potent inhibitors of Wnt/β-catenin, mTOR and STAT3 signaling in ovarian cancer

od Arend, Rebecca C., Londoño-Joshi, Angelina I., Gangrade, Abhishek, Katre, Ashwini A., Kurpad, Chandrika, Li, Yonghe, Samant, Rajeev S., Li, Pui-Kai, Landen, Charles N., Yang, Eddy S., Hidalgo, Bertha, Alvarez, Ronald D., Michael Straughn, John, Forero, Andres, Buchsbaum, Donald J.
izdano v Oncotarget (2016)

Correction: Niclosamide and its analogs are potent inhibitors of Wnt/β-catenin, mTOR and STAT3 signaling in ovarian cancer

od Arend, Rebecca C., Londoño-Joshi, Angelina I., Gangrade, Abhishek, Katre, Ashwini A., Kurpad, Chandrika, Li, Yonghe, Samant, Rajeev S., Li, Pui-Kai, Landen, Charles N., Yang, Eddy S., Hidalgo, Bertha, Alvarez, Ronald D., Straughn, John Michael, Forero, Andres, Buchsbaum, Donald J.
izdano v Oncotarget (2018)